BRPI0910832A2 - Derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk) - Google Patents

Derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk)

Info

Publication number
BRPI0910832A2
BRPI0910832A2 BRPI0910832-7A BRPI0910832A BRPI0910832A2 BR PI0910832 A2 BRPI0910832 A2 BR PI0910832A2 BR PI0910832 A BRPI0910832 A BR PI0910832A BR PI0910832 A2 BRPI0910832 A2 BR PI0910832A2
Authority
BR
Brazil
Prior art keywords
ampk
activators
protein kinase
activated protein
thienopyridone derivatives
Prior art date
Application number
BRPI0910832-7A
Other languages
English (en)
Inventor
Daniel Cravo
Franck Lepifre
Sophie Hallakou-Bozec
Christine Charon
Original Assignee
Merch Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910832(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merch Patent Ges Mit Beschränkter Haftung filed Critical Merch Patent Ges Mit Beschränkter Haftung
Publication of BRPI0910832A2 publication Critical patent/BRPI0910832A2/pt
Publication of BRPI0910832A8 publication Critical patent/BRPI0910832A8/pt
Publication of BRPI0910832B1 publication Critical patent/BRPI0910832B1/pt
Publication of BRPI0910832B8 publication Critical patent/BRPI0910832B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0910832A 2008-05-05 2009-04-08 derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos. BRPI0910832B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290423.6 2008-05-05
EP08290423 2008-05-05
PCT/EP2009/002606 WO2009135580A1 (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (4)

Publication Number Publication Date
BRPI0910832A2 true BRPI0910832A2 (pt) 2015-08-11
BRPI0910832A8 BRPI0910832A8 (pt) 2016-07-12
BRPI0910832B1 BRPI0910832B1 (pt) 2020-09-15
BRPI0910832B8 BRPI0910832B8 (pt) 2021-05-25

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910832A BRPI0910832B8 (pt) 2008-05-05 2009-04-08 derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.

Country Status (26)

Country Link
US (1) US8604202B2 (pt)
EP (1) EP2280952B1 (pt)
JP (1) JP5536757B2 (pt)
KR (2) KR20160038065A (pt)
CN (1) CN102015676B (pt)
AR (1) AR071530A1 (pt)
AU (1) AU2009243811B2 (pt)
BR (1) BRPI0910832B8 (pt)
CA (1) CA2723429C (pt)
CO (1) CO6331304A2 (pt)
CY (1) CY1113112T1 (pt)
DK (1) DK2280952T3 (pt)
EA (1) EA020773B1 (pt)
EC (1) ECSP10010654A (pt)
ES (1) ES2388485T3 (pt)
HR (1) HRP20120549T1 (pt)
IL (1) IL208988A (pt)
MX (1) MX2010011916A (pt)
MY (1) MY160357A (pt)
NZ (1) NZ589690A (pt)
PL (1) PL2280952T3 (pt)
PT (1) PT2280952E (pt)
SI (1) SI2280952T1 (pt)
UA (1) UA103617C2 (pt)
WO (1) WO2009135580A1 (pt)
ZA (1) ZA201008722B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草活性を有するケトスルタム類及びジケトピリジン類
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
US10308663B2 (en) 2015-06-16 2019-06-04 University Of Virginia Patent Foundation Inhibitors of PTP4A3 for the treatment of cancer
MA42456B1 (fr) 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US20190054096A1 (en) 2015-09-30 2019-02-21 Instituto De Medicina Molecular Methods for attenuating parasite virulence
WO2019067442A1 (en) * 2017-09-26 2019-04-04 Ideaya Biosciences, Inc. DIHYDROTHIENO [3,2-B] PYRIDINE COMPOUNDS
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
AU2006327898A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
UA103321C2 (ru) * 2008-04-11 2013-10-10 Мерк Патент Гмбх Производные тиенопиридона как активаторы amp-активированной протеинкиназы (амрк)

Also Published As

Publication number Publication date
CA2723429A1 (en) 2009-11-12
AU2009243811B2 (en) 2014-04-10
KR101648593B1 (ko) 2016-08-16
BRPI0910832B1 (pt) 2020-09-15
CN102015676A (zh) 2011-04-13
ES2388485T3 (es) 2012-10-15
BRPI0910832B8 (pt) 2021-05-25
US20110060001A1 (en) 2011-03-10
JP2011519876A (ja) 2011-07-14
ZA201008722B (en) 2012-01-25
AR071530A1 (es) 2010-06-23
EP2280952B1 (en) 2012-06-27
KR20160038065A (ko) 2016-04-06
PT2280952E (pt) 2012-09-28
MY160357A (en) 2017-02-28
PL2280952T3 (pl) 2012-10-31
NZ589690A (en) 2012-07-27
CN102015676B (zh) 2014-05-28
UA103617C2 (ru) 2013-11-11
WO2009135580A1 (en) 2009-11-12
CA2723429C (en) 2016-10-11
JP5536757B2 (ja) 2014-07-02
IL208988A (en) 2016-02-29
US8604202B2 (en) 2013-12-10
IL208988A0 (en) 2011-01-31
EP2280952A1 (en) 2011-02-09
DK2280952T3 (da) 2012-07-23
CO6331304A2 (es) 2011-10-20
AU2009243811A1 (en) 2009-11-12
EA201001733A1 (ru) 2011-06-30
HK1156313A1 (en) 2012-06-08
HRP20120549T1 (hr) 2012-07-31
BRPI0910832A8 (pt) 2016-07-12
EA020773B1 (ru) 2015-01-30
KR20110010757A (ko) 2011-02-07
MX2010011916A (es) 2010-11-26
CY1113112T1 (el) 2016-04-13
SI2280952T1 (sl) 2012-09-28
ECSP10010654A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
BRPI0910832A8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk)
BRPI0910439A2 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk)
NL301050I2 (nl) Relebactam of het monohydraat ervan
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
CU23828B1 (es) Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0920239A2 (pt) compostos heterocíclicos como inibidores de proteínas quinases
BRPI0911228A2 (pt) compostos e composições como inibidores de proteínas quinase
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
BRPI0814065A2 (pt) Derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
BRPI0717320A2 (pt) Triazóis bicíclicos como moduladores de proteína cinase
BRPI0910668A2 (pt) inibidores de proteína quinases
BR112012007300A2 (pt) derivador de pirimidina como inibidores proteína tirosina cinase 2
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0914544A2 (pt) derivados de pirimidona substituídos
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
BRPI0922042A2 (pt) derivados de 1-arilpirazol diméricos
BRPI0912475A8 (pt) compostos como inibidores de quinase
PT2513105E (pt) Derivados de 2-arilimidazole como inibidores da enzima pde10a
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.